This booklet is a guide to a man's prostate – what it is, what it does, and what can go wrong with it. It explains the three most common prostate problems, what changes to look out for, what to do if you think you have a prostate problem, and what might happen at the GP surgery.

References  

  • Ahmed HU, Bosaily AE-S, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017;389(10071):815–822.
  • Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA; 2005.
  • Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review. Eur Urol. 2009;55(4):864–75.
  • Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. 2013 May;63(5):800–9.
  • Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol. 2011 Apr;8(4):207–12.
  • Cancer Research UK. Cancer incidence for common cancers (2015) [Internet]. [cited 2016 May 19]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared
  • Cancer Research UK. Prostate cancer incidence statistics: Lifetime risk of prostate cancer (2012) [Internet]. [cited 2016 Jul 6]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Four
  • Cancer Research UK. Prostate cancer incidence statistics: Prostate cancer incidence by age (2011-2013) [Internet]. [cited 2016 Jun 9]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence
  • Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res (Phila Pa). 2011 Jan 13;4(4):486–501.
  • Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14(3):409–414.
  • Chapple C, Abrams P. Male Lower Urinary Tract Symptoms (LUTS): Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS. Société Internationale d’Urologie (SIU),; 2013.
  • Chen Y-C, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. The Prostate. 2008 Oct 1;68(14):1582–91.
  • Clearinghouse TNNK and UDI. Prostatitis: Inflammation of the Prostate [Internet]. [cited 2015 Jan 19]. Available from: http://kidney.niddk.nih.gov/KUDiseases/pubs/prostatitis/index.aspx#sec1
  • Clinical Effectiveness Group - British Association of Sexual Health and HIV. United Kingdom National guideline for the management of prostatitis (2008). 2008.
  • Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, Herwig R, et al. Gene polymorphisms and prostate cancer: the evidence. BJU Int. 2009;104(11):1560–1572.
  • Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Jan 6;23(7):1665–71.
  • Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int. 2008;102(8):981–6.
  • Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, et al. Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol. 2011 Oct;60(4):809–25.
  • Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, et al. Guidelines on non-neurogenic male lower urinary tract symptoms (LUTS) including benign prostatic obstruction [Internet]. European Association of Urology; 2016. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
  • Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer: Metabolic Factors and Prostate Cancer. Cancer. 2012 Dec 15;118(24):6199–206.
  • Hemminki K, Chen B. Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database. The Prostate. 2005 Oct 1;65(2):188–94.
  • Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, et al. Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. Eur Urol. 2012 Nov;62(5):910–6.
  • Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. Ecancermedicalscience. 2014;8:455.
  • Kheirandish P, Chinegwundoh F. Ethnic differences in prostate cancer. Br J Cancer. 2011 Aug 9;105(4):481–5.
  • Kiciński M, Vangronsveld J, Nawrot TS. An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis. Little J, editor. PLoS ONE. 2011 Oct 31;6(10):e27130.
  • Kirby M, Chapple C, Jackson G, Eardley I, Edwards D, Hackett G, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract. 2013 Jul;67(7):606–18.
  • Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med. 2015 Jul 30;13(1):171.
  • Lukacz ES, Sampselle C, Gray M, Macdiarmid S, Rosenberg M, Ellsworth P, et al. A healthy bladder: a consensus statement. Int J Clin Pract. 2011;65(10):1026–1036.
  • McNaughton-Collins M, Joyce G, Wise M, Pontari M. Prostatitis. In: Urologic Diseases in America US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, US: Government Publishing Office; 2007.
  • National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: assessment and management. NICE Clinical Guideline 97. (modified June 2015); 2010.
  • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
  • National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE Guideline 12. June 2015 [Internet]. 2015. Available from: http://www.nice.org.uk/guidance/ng12/evidence/full-guidance-65700685
  • Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2012;10(1):49–54.
  • Prostate Cancer UK. Consensus statements on PSA testing in asymptomatic men in the UK [Internet]. 2016. Available from: www.prostatecanceruk.org/PSAconsensusHP
  • Public Health England. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing [Internet]. GOV.UK; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing
  • Rebbeck TR, Devesa SS, Chang B-L, Bunker CH, Cheng I, Cooney K, et al. Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer. 2013;2013:1–12.
  • Rees J, Abrahams M, Doble A, Cooper A, the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015 Oct;116(4):509–25.
  • Rees J, Bultitude M, Challacombe B. The management of lower urinary tract symptoms in men. BMJ. 2014 Jun 24;348(1):g3861–g3861.
  • Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, et al. Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2011;173(12):1419–28.
  • Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK: Burden of male LUTS suggestive of BPH. BJU Int. 2015 Apr;115(4):508–19.
  • Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome: ANTIBIOTICS, ANTI-INFLAMMATORIES AND α-BLOCKERS IN CP/CPPS. BJU Int. 2012 Oct;110(7):1014–22.
  • World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf

About this publication  

Last updated April 2017 | To be reviewed April 2019

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication